• Skip to main content
  • Skip to footer
Eco Friendly CBD OIL

Eco Friendly CBD OIL

The Best Eco Friendly CBD Oil

  • Home
  • CBD Health
  • Cannabis News
  • Contact

Cannabis News

The Green Lady Dispensary Navigates First Year in Nantucket in the Age of Social Distancing: The Starting Line

February 16, 2021 by CBD OIL

Virginia, once a conservative stronghold, positioned itself to make history this month by becoming the first traditionally “Southern” state to legalize cannabis, possibly as soon as this summer. On Feb. 5, both chambers of the state’s General Assembly passed their own legalization bills that would also establish a state-run market and licensing system.

But Virginia is running into some of the same challenges as other states pursuing legalization: disagreements over license types, penalties for minors and the timing of the law’s implementation. Industry advocates are also concerned that more conservative elements of the state legislature will prevent equitable legalization in Virginia.

What’s happened so far?

Part of the state’s decriminalization bill signed by Democratic Gov. Ralph Northam in May 2020 directed the legislature to create a work group to study the possibility of legalization. Last month, Northam unveiled a legalization bill co-sponsored by multiple state legislators.

Two separate state legislative bills to legalize cannabis—HB2312 in the House and SB1406 in the Senate—have already passed. But the differences between the two bills must be resolved into a single resolution for Northam to sign. And that’s where things get tricky.

Where are things now?

“We’re at crossover. … The next thing that comes is conference,” said Chelsea Wise, founder of advocacy group Marijuana Justice, in a phone interview with Cannabis Business Times and Cannabis Dispensary.

She explained that the conference stage will involve private meetings between delegates from both the House and the Senate to resolve issues between the two bills, as well as changes to Northam’s initial legislation.

“We have two different versions of the bills and they are very different,” Wise said. She highlighted the ideological contrasts between the state’s relatively progressive House and its more conservative Senate. “[The State Senate] thinks we are moving too fast too soon.”

Wise and others have highlighted several key issues that need to be addressed for the state to achieve equitable legalization.

Social equity funding

Under the bill’s current structure, 30% of tax revenue from legal cannabis sales in Virginia would go to the state’s Cannabis Reinvestment Fund, a program to provide scholarships, training and workforce development opportunities in areas hit hardest by prohibition. Wise and other advocates like the ACLU of Virginia believe that figure is not high enough.

“We have taken livelihood from people, and that means we owe people money. … Only allocating 30% of the tax revenue to our reinvestment fund is an offensive offer,” she said. “We are pushing for 70% of those tax revenues to go back into the communities for grants, loans, for programs. … If we can’t even allocate at least a majority of the tax revenue to the people we have harmed now for generations, we are not actually serious about reconciling anything with Black people here in Virginia.”

Underage penalties

Early versions of the bill required that people who are under 21 and caught with cannabis must pay a fine and attend mandatory substance abuse classes. Some believe that the penalty for underage possession should be in line with the state’s penalties for underage possession of alcohol, currently punishable by a Class 1 misdemeanor. Other legislators believe that type of alignment is too harsh.

“We need to get that kid into some help, into some counseling—not jail,” said State Sen. Creigh Deeds, speaking about minors who are caught with cannabis.

State oversight of the industry

Northam has been vocal about wanting to achieve legalization during his term, which ends in January 2022. But the clock is ticking: State law in Virginia mandates that governors cannot serve consecutive terms, giving Northam less than a full year.

Northam’s plans are complicated by state senators calling for extra time to create a new commission specifically to regulate Virginia’s cannabis industry. Under Northam’s initial proposal, that role would fall to the state’s Alcoholic Beverage Commission (ABC), which regulates and operates Virginia liquor sales through state-run stores.

“I think we’re taking a responsible course. This is something that won’t happen overnight,” said State Sen. Adam Ebbin, sponsor of the Senate’s legalization bill.

“This thing is a 1,000-pound monster with tentacles that reach everywhere,” agreed State Sen. Scott Surovell during a subcommittee hearing. 

“We are supportive of the idea of an independent agency versus the ABC,” Wise said. “Our ABC is mostly law enforcement, like many others, … but the fact that it’s going to take so long is an issue.”

Legalization start date

Both the House and Senate bills wouldn’t allow recreational sales in Virginia until 2024. But Marijuana Justice and other advocacy groups are asking the General Assembly to speed up the legalization of simple possession in order to cut down on the number of Virginians getting arrested for cannabis. Virginia passed a decriminalization bill last year reducing the penalty for possessing an ounce or less to a $25 fine. Under legalization, that same amount would be completely legal, while possessing between an ounce and five pounds would result in a fine.

Like many other states, people of color in Virginia—particularly African-Americans—are arrested for cannabis far more frequently than other races.

Data from Virginia State Police indicates that while Black people comprise less than 20% of the state’s population, they account for over 45% of first-time cannabis arrests and nearly 53% of all subsequent offense arrests for possession of marijuana.

“If this legislation is to prioritize stopping the harm of arresting Black Virginians four times the rate of white Virginians for marijuana crimes—if we really want to stop that, we need a July 1 enactment date of legalization,” Wise said.

Vertical integration

Under the vertical integration model, a single company owns every part of the cannabis business, including grows and dispensaries. Supporters of vertical integration generally argue that it keeps costs down for consumers, adds efficiency to the market and upholds capitalistic principles. Opponents say vertical integration shuts out small operators who can’t afford to spend six or seven figures in licensing fees and overhead.

In Virginia, Northam’s initial proposal allowed for vertical integration, which is currently mandated in the state’s limited medical cannabis program. The House bill limits the practice by restricting companies to only one type of license. The Senate’s version allows for vertical integration but charges a $1-million licensing fee to help support the state’s cannabis equity programs.

Wise said that the debate doesn’t have to be black and white. She believes the state can benefit from vertical integration in the industry’s early stages, while providing opportunities to small entrepreneurs as things grow.

“What we’ve been really talking to the legislators about is yes, banning vertical integration—with some exceptions,” she said. “The medical industry is setting up, they could be the first providers, with some guardrails … [like] a sunset provision that once adult-use sales start, the would be backed out of the market.”

What happens next?

Once the General Assembly is able to work out the issues between the two versions of the bills, a final version will be created and voted upon. After approval, it will be sent to Northam’s desk to be signed into law.

Last week, Marijuana Justice and 23 other organizations—including prominent groups like the ACLU of Virginia, Minorities 4 Medical Marijuana, and the Drug Policy Alliance—sent a letter to governor Northam and state legislators laying out specific criteria to “legalize in a way that rights the wrongs of the disparate impact the War on Drugs has had on Black and Brown communities.”

“I would say that we would probably know more at the end of February, at least where the bills are [after] conference,” Wise said. “From there, we’ll decide if this bill is what we want or not what we want. I think we are going to see a big fight, just like every other state.”

 

Filed Under: Cannabis News

New Mexico House Health and Human Services Committee Passes Equity-Focused Legalization Bill

February 15, 2021 by CBD OIL

<![CDATA[

Gathered before a legislative crossroads, the New Mexico House Health and Human Services Committee made its intent clear on cannabis legalization: Social equity is going to be part of the process.

Today, the committee advanced House Bill 12 to the House Tax Committee, while ultimately tabling a similar legalization bill (House Bill 17) that did not include specific equity language. It was a clear signal to advocates and residents that the state is getting serious about developing a robust cannabis program.

The Drug Policy Alliance has regularly cited H.B. 12 this year as a favorable bill that might usher in a more progressive state marketplace. 

“Legalization must be responsive to the lives of New Mexicans, not solely business interests, and that means centering social justice, as the H.B. 12 introduced by Rep. Martinez, Rep. Andrea Romero and Rep. Deborah Armstrong does,” Emily Kaltenbach, senior director for Resident States and New Mexico for the Drug Policy Alliance, said in a public statement. “New Mexicans are absolutely ready to see marijuana legalization become a reality in the state, but they have made it clear that repairing the damage done by the drug war is non-negotiable. Any legislation considered this session must reinvest back into communities most harmed by drug prohibition, particularly Hispanic/Latino, Black and Native populations in New Mexico.”

According to the Drug Policy Alliance, “nearly three out of four New Mexicans approve of cannabis legalization with provisions in place to ensure tax revenue is reinvested back into communities, including 94% of Democrats, 93% of Independents and 46% of Republicans.”

]]>

Filed Under: Cannabis News

NORML Calls Upon President Biden to Pardon Non-Violent Federal Cannabis Offenses

February 15, 2021 by CBD OIL

Vertically integrated, multistate operator (MSO) Cresco Labs and its co-founder Joe Caltabiano have ended a multifaceted dispute in a Canadian court after Cresco alleged in a lawsuit that Caltabiano engaged in inappropriate behavior and created a “toxic work environment” while working at Cresco and breached his contract with the company, which he left last year.

On Jan. 29, Cresco filed a civil suit in British Columbia’s Supreme Court against Caltabiano, who was Cresco’s president and a member of its board of directors, and against Ken Amann and Choice Consolidation Corp. (Though it operates in the U.S., Cresco has an office in Vancouver, B.C., and is publicly traded on the Canadian Securities Exchange.)

By Feb. 4, the case was discontinued.

“The claims outlined in the lawsuit have been resolved through a mutual settlement agreement and Cresco has successfully mitigated the regulatory issues referred to in the complaint,” Cresco spokesperson Jason Erkes told Cannabis Business Times and Cannabis Dispensary in a Feb. 11 email. “The lawsuit has been discontinued in the Supreme Court of British Columbia.”

“This lawsuit was quickly dismissed on Feb. 4,” Shawna McGregor, a publicist who represents Caltabiano, told CBT and CD in a Feb. 12 email. “Had it proceeded, Mr. Caltabiano and Choice Consolidation Corp would have denied the allegations as untrue. Like all legitimate organizations, Choice Consolidation Corp. has every right to exist and operate within the U.S. cannabis marketplace.” 

In its suit, Cresco claimed that Caltabiano bullied and intimidated female employees at the company and “sought to embarrass his female employees at every turn.”

The company also alleged that Caltabiano and Amann, Cresco’s former chief financial officer and a former senior employee, “misused confidential information belonging to Cresco, including information about existing Cresco investors, and information about Cresco’s business plans and M&A targets” to benefit a separate, competing venture, the special purpose acquisition corporation (SPAC) Choice Consolidation.

RELATED: SPACs Are Changing the Cannabis Market M&A Landscape

In addition, Cresco alleged, “Caltabiano routinely directed subordinates to act without proper regard for regulatory compliance, and he personally showed disregard for regulatory compliance.” Cresco stated that it had to spend large sums of money to remedy a regulatory issue in Illinois that occurred because of “Caltabiano’s misconduct,” though the suit did not specify what the alleged misconduct was. Illinois regulators could not be reached for comment by CBT and CD‘s deadline.

The lawsuit also claims that when Cresco attempted to remove Caltabiano from various licenses, he “refused to cooperate, and advised Cresco that he would assist with such process only if he received substantial compensation for doing so.”

“In the face of Caltabiano’s intransigence, Cresco took steps to remove Caltabiano from various of its licenses in the absence of Caltabiano’s cooperation,” it states. “Aware that this was happening, Caltabiano actively intervened with applicable state authorities in Ohio and Arizona in an effort to retain or reinstate his position on Cresco’s licenses in those states. His active interference occurred as recently as January 22, 2021.” Regulators from both states declined comment for this story.

The Jan. 29 filing stated that Caltabiano “also enabled inappropriate, harassing and abusive language by male employees under his direct supervision towards female employees of Cresco.”

Female employees came forward with “numerous complaints,” which Cresco “confirmed through internal and externally led investigations, of harassing conduct by male employees within Caltabiano’s area of responsibility,” according to the complaint.

“Caltabiano repeatedly engaged in inappropriate, abusive, harassing and misogynistic conduct directed towards female employees of Cresco,” the lawsuit alleged. “While Caltabiano ‘managed’ … many of the employees through fear, bullying, and intimidation, he repeatedly belittled female employees for minor performance issues, made demeaning remarks about female employees’ appearance and personal characteristics, and sought to embarrass his female employees at every turn.”

Cresco planned to terminate Caltabiano for cause and, in February 2020, placed him on administrative leave, according to the suit, which then states that he resigned on March 2, 2020.

“Caltabiano continued as a director of Cresco until June 2020,” the complaint states. “He resigned as a director immediately before Cresco published its management information circular, knowing that the circular would disclose that he was not being nominated for re-election as a director of Cresco.”

 

Filed Under: Cannabis News

Cresco Labs Ends Lawsuit Against Co-Founder Joe Caltabiano

February 15, 2021 by CBD OIL

<![CDATA[

Vertically integrated, multistate operator (MSO) Cresco Labs and its co-founder Joe Caltabiano have ended a multifaceted dispute in a Canadian court after Cresco alleged in a lawsuit that Caltabiano engaged in inappropriate behavior and created a “toxic work environment” while working at Cresco and breached his contract with the company, which he left last year.

On Jan. 29, Cresco filed a civil suit in British Columbia’s Supreme Court against Caltabiano, who was Cresco’s president and a member of its board of directors, and against Ken Amann and Choice Consolidation Corp. (Though it operates in the U.S., Cresco has an office in Vancouver, B.C., and is publicly traded on the Canadian Securities Exchange.)

By Feb. 4, the case was discontinued.

“The claims outlined in the lawsuit have been resolved through a mutual settlement agreement and Cresco has successfully mitigated the regulatory issues referred to in the complaint,” Cresco spokesperson Jason Erkes told Cannabis Business Times and Cannabis Dispensary in a Feb. 11 email. “The lawsuit has been discontinued in the Supreme Court of British Columbia.”

“This lawsuit was quickly dismissed on Feb. 4,” Shawna McGregor, a publicist who represents Caltabiano, told CBT and CD in a Feb. 12 email. “Had it proceeded, Mr. Caltabiano and Choice Consolidation Corp would have denied the allegations as untrue. Like all legitimate organizations, Choice Consolidation Corp. has every right to exist and operate within the U.S. cannabis marketplace.” 

In its suit, Cresco claimed that Caltabiano bullied and intimidated female employees at the company and “sought to embarrass his female employees at every turn.”

The company also alleged that Caltabiano and Amann, Cresco’s former chief financial officer and a former senior employee, “misused confidential information belonging to Cresco, including information about existing Cresco investors, and information about Cresco’s business plans and M&A targets” to benefit a separate, competing venture, the special purpose acquisition corporation (SPAC) Choice Consolidation.

RELATED: SPACs Are Changing the Cannabis Market M&A Landscape

In addition, Cresco alleged, “Caltabiano routinely directed subordinates to act without proper regard for regulatory compliance, and he personally showed disregard for regulatory compliance.” Cresco stated that it had to spend large sums of money to remedy a regulatory issue in Illinois that occurred because of “Caltabiano’s misconduct,” though the suit did not specify what the alleged misconduct was. Illinois regulators could not be reached for comment by CBT and CD‘s deadline.

The lawsuit also claims that when Cresco attempted to remove Caltabiano from various licenses, he “refused to cooperate, and advised Cresco that he would assist with such process only if he received substantial compensation for doing so.”

"In the face of Caltabiano’s intransigence, Cresco took steps to remove Caltabiano from various of its licenses in the absence of Caltabiano’s cooperation,” it states. “Aware that this was happening, Caltabiano actively intervened with applicable state authorities in Ohio and Arizona in an effort to retain or reinstate his position on Cresco’s licenses in those states. His active interference occurred as recently as January 22, 2021.” Regulators from both states declined comment for this story.

The Jan. 29 filing stated that Caltabiano “also enabled inappropriate, harassing and abusive language by male employees under his direct supervision towards female employees of Cresco.”

Female employees came forward with “numerous complaints,” which Cresco “confirmed through internal and externally led investigations, of harassing conduct by male employees within Caltabiano’s area of responsibility,” according to the complaint.

“Caltabiano repeatedly engaged in inappropriate, abusive, harassing and misogynistic conduct directed towards female employees of Cresco,” the lawsuit alleged. “While Caltabiano ‘managed’ … many of the employees through fear, bullying, and intimidation, he repeatedly belittled female employees for minor performance issues, made demeaning remarks about female employees’ appearance and personal characteristics, and sought to embarrass his female employees at every turn.”

Cresco planned to terminate Caltabiano for cause and, in February 2020, placed him on administrative leave, according to the suit, which then states that he resigned on March 2, 2020.

“Caltabiano continued as a director of Cresco until June 2020,” the complaint states. “He resigned as a director immediately before Cresco published its management information circular, knowing that the circular would disclose that he was not being nominated for re-election as a director of Cresco.”

 

]]>

Filed Under: Cannabis News

Byers Scientific Announces New Company Structure to Deliver Innovative and Sustainable Industrial-Scale Odor Mitigation Solutions

February 15, 2021 by CBD OIL

Name: Philip Goldberg

Location: Frederick, Md.

Title: CEO, Green Leaf Medical

One word to describe your cultivation style: Intelligent

Indoor, outdoor, greenhouse or a combination: Indoor

Can you share a bit of your background and how you and your company got to the present day?

Green Leaf Medical was formed in 2014 by myself and my brother, Kevin Goldberg. I had been running an advertising agency I started from the ground up in 1998 and Kevin was working at a law firm he founded shortly after graduating from Catholic University School of Law in 1995. After forming the company in 2014, we spent the next two years positioning Green Leaf to secure one of a limited number of licenses to cultivate medical cannabis in Maryland. In August of 2016, we were notified that our application had been approved and that we had received the highest score out of 146 applicants for cultivation. We then began the arduous task of raising capital to construct our 42,000-square-foot cultivation facility. We raised approximately $9 million through the sale of equity. The construction took 12 months and when it was completed, we had a state of the art, fully automated cultivation facility. We began cultivating in September 2017 and had our first harvest in January of 2018. At this point, we developed the gLeaf brand that is associated with all our products. The facility currently produces approximately 1,000 pounds of dry cannabis per month. From there, we acquired the first extraction and dispensary licenses issued in the state.

While working to build our brand in Maryland, we submitted an application for one of the limited number of cannabis licenses being issued in Pennsylvania. We won a license in the South-Central region, where we had purchased the former Seaton Leather manufacturing facility. This facility had been the largest employer in the area and economically devastated the community when it shut down nearly a decade prior. We raised an additional $13 million to convert the first 100,000 square feet of the 275,000-square-foot facility into a state-of-the-art cultivating and extraction facility. The facility became operational in April of 2019 and currently produces approximately 1,700 pounds per month of dry cannabis. In late 2019, we sold the facility to Innovative Industrial Properties for $13 million in a sale-leaseback transaction that would free up capital to continue expansion.

With Pennsylvania and Maryland operational, we turned our focus to Ohio. We were successful in winning a dispensary license in Warren, Ohio, where we serve hundreds of patients per day.

Next, we applied for one of five vertical licenses being issued in Virginia. We were successful in winning a license in Richmond, Va., and used the proceeds of the sale-leaseback in Pennsylvania to fund the buildout of an 82,000-square-foot cultivation, extraction and retail facility. Ultimately, we executed on a $20 million sale-leaseback with Innovative Industrial Properties, which completed the construction of the Richmond facility and provided us with growth and operational capital. The Richmond facility can produce 2,200 pounds of dry cannabis per month.

Finally, we recently began construction of the remaining 175,000 square feet of space in our Saxton, Penn., facility. Again, we funded this expansion through an additional sale-leaseback with Innovative Industrial for $30 million. We are building a triple stacked LED grow that will add 5,000 additional pounds per month to the existing 1,600 we are currently producing in Pennsylvania.

All told, our operations in the Mid-Atlantic region reach a population of approximately 34 million. Our facilities and current buildouts will allow Green Leaf to produce nearly 10,000 pounds of cannabis per month.

What tool or software in your cultivation space can you not live without?

Automated irrigation and environmental controls are definitely important, along with our proprietary inventory control and gLeaf live marketplace.

What purchase of $100 or less has most positively impacted your business in the last six months?

Buck boosters for our grow lights. Buck-boost transformers are small, single-phase transformers designed to reduce (buck) or raise (boost) line voltage up to 20%. These units boost the wattage of our grow lights from 1,000 watts to 1,150 watts. The units cost around $125 retail; however, our in-house engineers, Alan and Glenn Mountain, were able to build our own buck boosters for around $40. This has had a measurable, positive impact on our yields.

What cultivation technique are you most interested in right now, and what are you actively studying (the most)?

We are currently migrating to LED in flower so that we can stack our production and lower our energy costs. We are also focusing on perfecting tissue culture.

How has a failure, or apparent failure, set you up for later success? Do you have a “favorite failure” of yours?

It seems like every day there are new lessons to learn, whether it is undersized dehumidification, improperly placed floor drains, rolling benches that weren’t properly leveled or a hundred other things. One of my favorites would be the time a water line ruptured in one of the first flower rooms we constructed, flooding the floor. We thought it was no big deal because we were “smart” enough to include trench drains in our design. It wasn’t until we started pushing water toward the drains that we realized the floor was not sloped appropriately to move the water to the drain, rendering the “smart” trench drains useless. You can bet that on every construction project after that we made sure the slope was correct!

What advice would you give to a smart, driven grower about to enter the legal, regulated industry? What advice should they ignore?

Ignore nothing. There is always something to learn from other operators. Having said that, trust your instincts and develop your own style. There is no one “right” way to grow. Be prepared to get up early and stay late. Appreciate that producing construction plans, raising capital, growing quality cannabis and reducing your cost per pound is only part of running a successful operation. Even if you do everything else right, if you aren’t focused on your employees and corporate culture, it can all fall apart. At the end of the day, your success and happiness will in large part depend on the success and happiness of your employees.

How do you deal with burnout?

I try to keep a good balance between work, family and friends.

How do you motivate your employees/team?

The interaction and communication between our managers/leads and our employees is critical to motivating the team. We also have employee appreciation parties, we offer matching 401k, 90% health care coverage, free mental health services and more.

What keeps you awake at night?

Everything! Employee health due to COVID, plant health, financial well-being of the company, status of pending applications, compliance audits, inventory audits, etc.

What helps you sleep at night?

Having faced so many challenges over the past six years, I have come to realize that there is no problem that can’t be fixed. I may need to bring in someone smarter than me to think through the issue, but with the right people, we can overcome just about anything.

Editor’s Note: This interview has been edited for style, length and clarity.

 

Filed Under: Cannabis News

State Legalization Bills Are Flying, M&A Is Heating Up: Week in Review

February 13, 2021 by CBD OIL

Anarkoooo | Adobe Stock

As the state-by-state markets continue to grow, major players outside the cannabis industry are looking for a way in. And those already with a footprint in the sector are poised to go bigger.

Earlier this month, a blockbuster deal kicked off the 2021 cannabis merger-and-acquisition season, when Ireland-based Jazz Pharmaceuticals inked a $7.2-billion deal to acquire United Kingdom-based GW Pharmaceuticals, the manufacturer of the Food and Drug Administration-approved Epidiolex. It was the biggest handshake yet for the cannabis industry, and it could be just the beginning of what’s to come in a global market still in its infancy.

At Fox Rothschild, a Philadelphia-based law firm with a national cannabis practice group, Partner Melissa Sanders and Associate Jared Schwass told clients there is much more room for businesses to expand in an alert they released Feb. 1.

Sanders advises corporate clients on a wide range of business matters, with a particular focus on mergers and acquisitions, private placements of securities, financing transactions and ownership transition programs. Schwass is an attorney in the corporate department and a member of the firm’s Cannabis Law Practice Group. He advises businesses entering and operating in the legalized cannabis market on regulatory compliance, risk mitigation and business transactions.

“At the end of 2020, we saw an uptick in merger-and-acquisition activity as the industry shook off some pandemic-related instability, and we expect that trend to increase significantly in 2021,” they said in the alert.

“Despite abundant money available to the large multi-state operators (MSOs), most cannabis companies still have relatively limited avenues to raise capital due to the federal illegality of the industry,” they said. “However, that may change soon with the democrats now controlling both houses of Congress and the White House.”

When cannabis is descheduled, Sanders and Schwass said they anticipate an influx of cash into the sector, as previously reluctant investors and institutions enter the market without fear of federal repercussions.

Here, Sanders and Schwass share more about M&A activity trends, anticipations and indicators, and how MSOs and smaller businesses alike can position themselves for possible growth opportunities.                        

Tony Lange: What stood out most about how M&A activities shaped up in the 2020 cannabis industry?

Fox Rothschild | foxrothschild.com

Melissa Sanders, partner 

Melissa Sanders: I think we were seeing a lot of the distressed assets being snapped up. And even outside of the distressed assets, there were some good deals to be had. As we’re moving into 2021, that’s continuing. But I think that with the change in the Senate and legalization potentially on the forefront, additional capital is coming in and we’re going to see more M&A overall.

Jared Schwass: When COVID-19 first hit, there was kind of a lull in activity. Then, when medical necessities and distressed assets became available, that’s when the serial acquirers were buying up. And then we did see, towards the end, a couple of mergers that that were big news. I feel like more of that’s going to happen in 2021.

TL: How much would cannabis legislation at the federal level impact M&A activity?

MS: Federal legislation has some weight. I don’t want to overstate it, because we have to wait and see, but I do think it will bring in some potential money of folks who were still a little hesitant to maybe get into the business and essentially raise capital or put capital into other companies. The actual operators, they’ve already made the bet on cannabis. So, for them, a lot of it has been dependent on where the capital’s at.

JS: In addition to the increased capital that we can see, I believe with the descheduling on the Controlled Substances Act, that we’ll see major players outside of the cannabis industry start looking at trying to get into the industry.

TL: Regardless of the makeup of Congress, what are your anticipations for the rest of 2021?

MS: Regardless of what does happen at the federal level, I think M&A activity is going to be on the upswing. There are still a lot of good deals to be had out there. I also think people are anticipating and hopeful for an economic turnaround. So, deals are going to continue to happen and continue to grow.

I do think that we’re in a little bit of a different position than we were the last time there was this huge amount of M&A activity in the sense that companies are more mature. They’re seeing the things that maybe went wrong or weren’t ideal in former deals. So, although the increase is going to make for more competition for acquirers, I don’t think it’s going to be the same as it was in 2019, when people were really overlooking some real blemishes in companies just to keep growing and get in there. Now people really are looking at the fundamentals of the business and making sure they’ve got the corporate books and things like that.

-Melissa Sanders, Fox Rothschild partner 

JS: To add to that, regardless of what happens in Congress and the Senate, I think that M&A activity is going to still continue. We’re going to see a significant activity in that area, and there’s going to be a lot of consolidation in the coming years.

TL: Do you think small-scale cannabis businesses are a dying breed?

MS: I personally don’t think so, because there is a market for these independent companies and independent brands. That market is going to remain in cannabis and other industries. I do think that it’s going to be a lot harder for them to survive and compete, but I don’t think it’s a dying breed.

We’re still seeing a lot of small, one-off acquisitions. A lot of them are actually growing but not looking to necessarily become a huge MSO, although some of them are.

Fox Rothschild | foxrothschild.com

Jared Schwass, associate

JS: I don’t think it’s dying. I think it’s difficult, especially the small farmers up in Northern California are struggling. But I think through struggle comes perseverance. There is something to be said about these small farms and these small kind of craft brands that there still is a market for them, and there will continue to be a market for them.

TL: How can some of the small-scale cannabis businesses make themselves attractable for sale, if that’s the path they want to go?

MS: If they want to make themselves attractive, the biggest thing is getting everything in order, making sure they’ve got records or descriptions, depending on how old the company is; there was a time when companies weren’t keeping great records. If they don’t have them, they don’t have them, but getting whatever they do have in order, looking at where there are holes to the extent that they’re fixable, to work on those, and also just getting kind of all of their paperwork in order to make sure they’re tracking things will help. When an acquirer comes in, they’re going to want to do a lot of due diligence on the business and legal side. And, so, being able to present those materials quickly is important.

JS: I second that. Clean books are very important so there’s no questions on ownership or taxes or anything like that. And, generally speaking, good cashflow, not a lot of debt on the books, that type of stuff is important too.

TL: How can MSOs stay on top of the competitive M&A market so they can take advantage of opportunities as they arise?

MS: That’s a good question. A lot of it is just staying on top of who all of the operators are in the areas that make sense for you strategically. I think MSOs are going to acquire strategically this year, and making sure that they understand who the players are in each market, and whether those players might be open to sale, can help them approach the right people at the right time.

JS: Knowing who to acquire, what licenses, where, what states are opening up and doing your own market research is valuable in making sure that if you want to enter into a market in a different state, that that’s going to work for your business. Just doing your own due diligence and research in the market is essential to taking advantage of those opportunities.

TL: What sparks companies to decide whether a merger is right for them, or they’re better off pursing an acquisition?

MS: The same deal could really, in most cases, be structured as a merger or an acquisition just depending on certain legal points and tax points. I think we are seeing a lot of the larger deals as mergers, in large part because it’s going to be stock-for-stock and not a lot of cash. A lot of the stock deals are more merger-oriented and a lot of the cash deals may be structured as acquisitions, but that’s not 100% across the board. And definitely the smaller one-off deals, those are almost always structured as acquisitions and not mergers.

JS: Generally speaking, the bigger deals are to be more of a merger, when two bigger companies come together, whereas when you have a bigger company looking to just expand its market in a specific area, just buying a small business here and there, those are going to be obviously acquisitions.

TL: What states or regions do you forecast being hotbeds for M&A activity in the U.S.?

MS: I do think states that recently passed adult-use legalization, especially those that previously had medical programs, a lot of times there are going to be procedures for them to convert their companies, and those states will probably see M&A activity.

JS: California has a bunch of independent operators, and I believe the market is right for consolidation if companies can find synergies within themselves. Regardless of what happens in Congress, I think that we’re going to see continued M&A activity just because the market, the industry itself, is in its infancy and people are growing. But if the federal government decides to deschedule or legalize cannabis this year, I believe we will see a significant uptick in that activity.

Editor’s Note: This interview has been edited for style, length and clarity.

Filed Under: Cannabis News

South Dakota to Postpone Implementation of Voter-Approved Medical Cannabis Measure

February 12, 2021 by CBD OIL

Anarkoooo | Adobe Stock

As the state-by-state markets continue to grow, major players outside the cannabis industry are looking for a way in. And those already with a footprint in the sector are poised to go bigger.

Earlier this month, a blockbuster deal kicked off the 2021 cannabis merger-and-acquisition season, when Ireland-based Jazz Pharmaceuticals inked a $7.2-billion deal to acquire United Kingdom-based GW Pharmaceuticals, the manufacturer of the Food and Drug Administration-approved Epidiolex. It was the biggest handshake yet for the cannabis industry, and it could be just the beginning of what’s to come in a global market still in its infancy.

At Fox Rothschild, a Philadelphia-based law firm with a national cannabis practice group, Partner Melissa Sanders and Associate Jared Schwass told clients there is much more room for businesses to expand in an alert they released Feb. 1.

Sanders advises corporate clients on a wide range of business matters, with a particular focus on mergers and acquisitions, private placements of securities, financing transactions and ownership transition programs. Schwass is an attorney in the corporate department and a member of the firm’s Cannabis Law Practice Group. He advises businesses entering and operating in the legalized cannabis market on regulatory compliance, risk mitigation and business transactions.

“At the end of 2020, we saw an uptick in merger-and-acquisition activity as the industry shook off some pandemic-related instability, and we expect that trend to increase significantly in 2021,” they said in the alert.

“Despite abundant money available to the large multi-state operators (MSOs), most cannabis companies still have relatively limited avenues to raise capital due to the federal illegality of the industry,” they said. “However, that may change soon with the democrats now controlling both houses of Congress and the White House.”

When cannabis is descheduled, Sanders and Schwass said they anticipate an influx of cash into the sector, as previously reluctant investors and institutions enter the market without fear of federal repercussions.

Here, Sanders and Schwass share more about M&A activity trends, anticipations and indicators, and how MSOs and smaller businesses alike can position themselves for possible growth opportunities.                        

Tony Lange: What stood out most about how M&A activities shaped up in the 2020 cannabis industry?

Fox Rothschild | foxrothschild.com

Melissa Sanders, partner 

Melissa Sanders: I think we were seeing a lot of the distressed assets being snapped up. And even outside of the distressed assets, there were some good deals to be had. As we’re moving into 2021, that’s continuing. But I think that with the change in the Senate and legalization potentially on the forefront, additional capital is coming in and we’re going to see more M&A overall.

Jared Schwass: When COVID-19 first hit, there was kind of a lull in activity. Then, when medical necessities and distressed assets became available, that’s when the serial acquirers were buying up. And then we did see, towards the end, a couple of mergers that that were big news. I feel like more of that’s going to happen in 2021.

TL: How much would cannabis legislation at the federal level impact M&A activity?

MS: Federal legislation has some weight. I don’t want to overstate it, because we have to wait and see, but I do think it will bring in some potential money of folks who were still a little hesitant to maybe get into the business and essentially raise capital or put capital into other companies. The actual operators, they’ve already made the bet on cannabis. So, for them, a lot of it has been dependent on where the capital’s at.

JS: In addition to the increased capital that we can see, I believe with the descheduling on the Controlled Substances Act, that we’ll see major players outside of the cannabis industry start looking at trying to get into the industry.

TL: Regardless of the makeup of Congress, what are your anticipations for the rest of 2021?

MS: Regardless of what does happen at the federal level, I think M&A activity is going to be on the upswing. There are still a lot of good deals to be had out there. I also think people are anticipating and hopeful for an economic turnaround. So, deals are going to continue to happen and continue to grow.

I do think that we’re in a little bit of a different position than we were the last time there was this huge amount of M&A activity in the sense that companies are more mature. They’re seeing the things that maybe went wrong or weren’t ideal in former deals. So, although the increase is going to make for more competition for acquirers, I don’t think it’s going to be the same as it was in 2019, when people were really overlooking some real blemishes in companies just to keep growing and get in there. Now people really are looking at the fundamentals of the business and making sure they’ve got the corporate books and things like that.

-Melissa Sanders, Fox Rothschild partner 

JS: To add to that, regardless of what happens in Congress and the Senate, I think that M&A activity is going to still continue. We’re going to see a significant activity in that area, and there’s going to be a lot of consolidation in the coming years.

TL: Do you think small-scale cannabis businesses are a dying breed?

MS: I personally don’t think so, because there is a market for these independent companies and independent brands. That market is going to remain in cannabis and other industries. I do think that it’s going to be a lot harder for them to survive and compete, but I don’t think it’s a dying breed.

We’re still seeing a lot of small, one-off acquisitions. A lot of them are actually growing but not looking to necessarily become a huge MSO, although some of them are.

Fox Rothschild | foxrothschild.com

Jared Schwass, associate

JS: I don’t think it’s dying. I think it’s difficult, especially the small farmers up in Northern California are struggling. But I think through struggle comes perseverance. There is something to be said about these small farms and these small kind of craft brands that there still is a market for them, and there will continue to be a market for them.

TL: How can some of the small-scale cannabis businesses make themselves attractable for sale, if that’s the path they want to go?

MS: If they want to make themselves attractive, the biggest thing is getting everything in order, making sure they’ve got records or descriptions, depending on how old the company is; there was a time when companies weren’t keeping great records. If they don’t have them, they don’t have them, but getting whatever they do have in order, looking at where there are holes to the extent that they’re fixable, to work on those, and also just getting kind of all of their paperwork in order to make sure they’re tracking things will help. When an acquirer comes in, they’re going to want to do a lot of due diligence on the business and legal side. And, so, being able to present those materials quickly is important.

JS: I second that. Clean books are very important so there’s no questions on ownership or taxes or anything like that. And, generally speaking, good cashflow, not a lot of debt on the books, that type of stuff is important too.

TL: How can MSOs stay on top of the competitive M&A market so they can take advantage of opportunities as they arise?

MS: That’s a good question. A lot of it is just staying on top of who all of the operators are in the areas that make sense for you strategically. I think MSOs are going to acquire strategically this year, and making sure that they understand who the players are in each market, and whether those players might be open to sale, can help them approach the right people at the right time.

JS: Knowing who to acquire, what licenses, where, what states are opening up and doing your own market research is valuable in making sure that if you want to enter into a market in a different state, that that’s going to work for your business. Just doing your own due diligence and research in the market is essential to taking advantage of those opportunities.

TL: What sparks companies to decide whether a merger is right for them, or they’re better off pursing an acquisition?

MS: The same deal could really, in most cases, be structured as a merger or an acquisition just depending on certain legal points and tax points. I think we are seeing a lot of the larger deals as mergers, in large part because it’s going to be stock-for-stock and not a lot of cash. A lot of the stock deals are more merger-oriented and a lot of the cash deals may be structured as acquisitions, but that’s not 100% across the board. And definitely the smaller one-off deals, those are almost always structured as acquisitions and not mergers.

JS: Generally speaking, the bigger deals are to be more of a merger, when two bigger companies come together, whereas when you have a bigger company looking to just expand its market in a specific area, just buying a small business here and there, those are going to be obviously acquisitions.

TL: What states or regions do you forecast being hotbeds for M&A activity in the U.S.?

MS: I do think states that recently passed adult-use legalization, especially those that previously had medical programs, a lot of times there are going to be procedures for them to convert their companies, and those states will probably see M&A activity.

JS: California has a bunch of independent operators, and I believe the market is right for consolidation if companies can find synergies within themselves. Regardless of what happens in Congress, I think that we’re going to see continued M&A activity just because the market, the industry itself, is in its infancy and people are growing. But if the federal government decides to deschedule or legalize cannabis this year, I believe we will see a significant uptick in that activity.

Editor’s Note: This interview has been edited for style, length and clarity.

Filed Under: Cannabis News

How Green Leaf Medical’s Philip Goldberg Works: Cannabis Workspace

February 12, 2021 by CBD OIL

Anarkoooo | Adobe Stock

As the state-by-state markets continue to grow, major players outside the cannabis industry are looking for a way in. And those already with a footprint in the sector are poised to go bigger.

Earlier this month, a blockbuster deal kicked off the 2021 cannabis merger-and-acquisition season, when Ireland-based Jazz Pharmaceuticals inked a $7.2-billion deal to acquire United Kingdom-based GW Pharmaceuticals, the manufacturer of the Food and Drug Administration-approved Epidiolex. It was the biggest handshake yet for the cannabis industry, and it could be just the beginning of what’s to come in a global market still in its infancy.

At Fox Rothschild, a Philadelphia-based law firm with a national cannabis practice group, Partner Melissa Sanders and Associate Jared Schwass told clients there is much more room for businesses to expand in an alert they released Feb. 1.

Sanders advises corporate clients on a wide range of business matters, with a particular focus on mergers and acquisitions, private placements of securities, financing transactions and ownership transition programs. Schwass is an attorney in the corporate department and a member of the firm’s Cannabis Law Practice Group. He advises businesses entering and operating in the legalized cannabis market on regulatory compliance, risk mitigation and business transactions.

“At the end of 2020, we saw an uptick in merger-and-acquisition activity as the industry shook off some pandemic-related instability, and we expect that trend to increase significantly in 2021,” they said in the alert.

“Despite abundant money available to the large multi-state operators (MSOs), most cannabis companies still have relatively limited avenues to raise capital due to the federal illegality of the industry,” they said. “However, that may change soon with the democrats now controlling both houses of Congress and the White House.”

When cannabis is descheduled, Sanders and Schwass said they anticipate an influx of cash into the sector, as previously reluctant investors and institutions enter the market without fear of federal repercussions.

Here, Sanders and Schwass share more about M&A activity trends, anticipations and indicators, and how MSOs and smaller businesses alike can position themselves for possible growth opportunities.                        

Tony Lange: What stood out most about how M&A activities shaped up in the 2020 cannabis industry?

Fox Rothschild | foxrothschild.com

Melissa Sanders, partner 

Melissa Sanders: I think we were seeing a lot of the distressed assets being snapped up. And even outside of the distressed assets, there were some good deals to be had. As we’re moving into 2021, that’s continuing. But I think that with the change in the Senate and legalization potentially on the forefront, additional capital is coming in and we’re going to see more M&A overall.

Jared Schwass: When COVID-19 first hit, there was kind of a lull in activity. Then, when medical necessities and distressed assets became available, that’s when the serial acquirers were buying up. And then we did see, towards the end, a couple of mergers that that were big news. I feel like more of that’s going to happen in 2021.

TL: How much would cannabis legislation at the federal level impact M&A activity?

MS: Federal legislation has some weight. I don’t want to overstate it, because we have to wait and see, but I do think it will bring in some potential money of folks who were still a little hesitant to maybe get into the business and essentially raise capital or put capital into other companies. The actual operators, they’ve already made the bet on cannabis. So, for them, a lot of it has been dependent on where the capital’s at.

JS: In addition to the increased capital that we can see, I believe with the descheduling on the Controlled Substances Act, that we’ll see major players outside of the cannabis industry start looking at trying to get into the industry.

TL: Regardless of the makeup of Congress, what are your anticipations for the rest of 2021?

MS: Regardless of what does happen at the federal level, I think M&A activity is going to be on the upswing. There are still a lot of good deals to be had out there. I also think people are anticipating and hopeful for an economic turnaround. So, deals are going to continue to happen and continue to grow.

I do think that we’re in a little bit of a different position than we were the last time there was this huge amount of M&A activity in the sense that companies are more mature. They’re seeing the things that maybe went wrong or weren’t ideal in former deals. So, although the increase is going to make for more competition for acquirers, I don’t think it’s going to be the same as it was in 2019, when people were really overlooking some real blemishes in companies just to keep growing and get in there. Now people really are looking at the fundamentals of the business and making sure they’ve got the corporate books and things like that.

-Melissa Sanders, Fox Rothschild partner 

JS: To add to that, regardless of what happens in Congress and the Senate, I think that M&A activity is going to still continue. We’re going to see a significant activity in that area, and there’s going to be a lot of consolidation in the coming years.

TL: Do you think small-scale cannabis businesses are a dying breed?

MS: I personally don’t think so, because there is a market for these independent companies and independent brands. That market is going to remain in cannabis and other industries. I do think that it’s going to be a lot harder for them to survive and compete, but I don’t think it’s a dying breed.

We’re still seeing a lot of small, one-off acquisitions. A lot of them are actually growing but not looking to necessarily become a huge MSO, although some of them are.

Fox Rothschild | foxrothschild.com

Jared Schwass, associate

JS: I don’t think it’s dying. I think it’s difficult, especially the small farmers up in Northern California are struggling. But I think through struggle comes perseverance. There is something to be said about these small farms and these small kind of craft brands that there still is a market for them, and there will continue to be a market for them.

TL: How can some of the small-scale cannabis businesses make themselves attractable for sale, if that’s the path they want to go?

MS: If they want to make themselves attractive, the biggest thing is getting everything in order, making sure they’ve got records or descriptions, depending on how old the company is; there was a time when companies weren’t keeping great records. If they don’t have them, they don’t have them, but getting whatever they do have in order, looking at where there are holes to the extent that they’re fixable, to work on those, and also just getting kind of all of their paperwork in order to make sure they’re tracking things will help. When an acquirer comes in, they’re going to want to do a lot of due diligence on the business and legal side. And, so, being able to present those materials quickly is important.

JS: I second that. Clean books are very important so there’s no questions on ownership or taxes or anything like that. And, generally speaking, good cashflow, not a lot of debt on the books, that type of stuff is important too.

TL: How can MSOs stay on top of the competitive M&A market so they can take advantage of opportunities as they arise?

MS: That’s a good question. A lot of it is just staying on top of who all of the operators are in the areas that make sense for you strategically. I think MSOs are going to acquire strategically this year, and making sure that they understand who the players are in each market, and whether those players might be open to sale, can help them approach the right people at the right time.

JS: Knowing who to acquire, what licenses, where, what states are opening up and doing your own market research is valuable in making sure that if you want to enter into a market in a different state, that that’s going to work for your business. Just doing your own due diligence and research in the market is essential to taking advantage of those opportunities.

TL: What sparks companies to decide whether a merger is right for them, or they’re better off pursing an acquisition?

MS: The same deal could really, in most cases, be structured as a merger or an acquisition just depending on certain legal points and tax points. I think we are seeing a lot of the larger deals as mergers, in large part because it’s going to be stock-for-stock and not a lot of cash. A lot of the stock deals are more merger-oriented and a lot of the cash deals may be structured as acquisitions, but that’s not 100% across the board. And definitely the smaller one-off deals, those are almost always structured as acquisitions and not mergers.

JS: Generally speaking, the bigger deals are to be more of a merger, when two bigger companies come together, whereas when you have a bigger company looking to just expand its market in a specific area, just buying a small business here and there, those are going to be obviously acquisitions.

TL: What states or regions do you forecast being hotbeds for M&A activity in the U.S.?

MS: I do think states that recently passed adult-use legalization, especially those that previously had medical programs, a lot of times there are going to be procedures for them to convert their companies, and those states will probably see M&A activity.

JS: California has a bunch of independent operators, and I believe the market is right for consolidation if companies can find synergies within themselves. Regardless of what happens in Congress, I think that we’re going to see continued M&A activity just because the market, the industry itself, is in its infancy and people are growing. But if the federal government decides to deschedule or legalize cannabis this year, I believe we will see a significant uptick in that activity.

Editor’s Note: This interview has been edited for style, length and clarity.

Filed Under: Cannabis News

New Guidance on Waste Disposal for Hemp Producers

February 12, 2021 by CBD OIL

On January 15, 2021, the USDA published its final rule on US hemp production. The rule, which becomes effective on March 22, 2021, expands and formalizes previous guidance related to waste disposal of noncompliant or “hot” crops (crops with a THC concentration above .3 percent). Importantly for the industry, the new disposal rules remove unduly burdensome DEA oversight and provides for remediation options.

Producers will not be required to use a DEA reverse distributor or law enforcement to dispose of noncompliant plants. Instead, producers will be able to use common on-farm practices for disposal. Some of these disposal options include, but are not limited to, plowing under non-compliant plants, composting into “green manure” for use on the same land, tilling, disking, burial or burning. By eliminating DEA involvement from this process, the USDA rules serve to streamline disposal options for producers of this agricultural commodity.

Alternatively, the final rule permits “remediation” of noncompliant plants. Allowing producers to remove and destroy noncompliant flower material – while retaining stalk, stems, leaf material and seeds – is an important crop and cost-saving measure for producers, especially smaller producers. Remediation can also occur by shredding the entire plant to create “biomass” and then re-testing the biomass for compliance. Biomass that fails the retesting is noncompliant hemp and must be destroyed. The USDA has issued an additional guidance document on remediation. Importantly, this guidance advises that lots should be kept separate during the biomass creation process, remediated biomass must be stored and labeled apart from each other and from other compliant hemp lots and seeds removed from non-compliant hemp should not be used for propagative purposes.

The final rules have strict record keeping requirements, such rules ultimately protect producers and should be embraced. For example, producers must document the disposal of all noncompliant plants by completing the “USDA Hemp Plan Producer Disposal Form.” Producers must also maintain records on all remediated plants, including an original copy of the resample test results. Records must be kept for a minimum of three years. While USDA has not yet conducted any random audits, the department may conduct random audits of licensees.

Although this federal guidance brings some clarity to hemp producers, there still remains litigation risks associated with waste disposal. There are unknown environmental impacts from the industry and there is potential tort liability or compliance issues with federal and state regulations. For example, as mentioned above, although burning and composting disposal options for noncompliant plants, the final rule does not address the potential risk for nuisance complaints from smoke or odor associated with these methods.

At the federal level, there could be compliance issues with the Resource Conservation and Recovery Act (RCRA), Comprehensive Environmental Response Compensation and Liability Act (CERCLA) and ancillary regulations like Occupation Safety and Health Administration (OSHA). In addition to government enforcement under RCRA and CERCLA, these hazardous waste laws also permit private party suits. Although plant material from cultivation is not considered hazardous, process liquids from extraction or distillation (ethanol, acetone, etc.) are hazardous. Under RCRA, an individual can bring an “imminent and substantial endangerment” citizen suit against anyone generating or storing hazardous waste in a way the presents imminent and substantial endangerment to health or the environment. Under CERCLA, private parties who incur costs for removal or remediation may sue to recover costs from other responsible parties.

At the state level, there could be issues with state agency guidance and state laws. For example, California has multiple state agencies that oversee cannabis and hemp production and disposal. CA Prop 65 mandates warnings for products with certain chemicals, including pesticides, heavy metals and THC. The California Environmental Quality Act (CEQA) requires the evaluation of the environmental impact of runoff or pesticides prior to issuing a cultivation permit. Both environmental impact laws permit a form of private action.

Given the varied and evolving rules and regulation on hemp cultivation, it remains essential for hemp producers to seek guidance and the help of professionals when entering this highly regulated industry.

Filed Under: Cannabis News

Colorado Cannabis Sales Approaching $10 Billion

February 11, 2021 by CBD OIL

Anarkoooo | Adobe Stock

As the state-by-state markets continue to grow, major players outside the cannabis industry are looking for a way in. And those already with a footprint in the sector are poised to go bigger.

Earlier this month, a blockbuster deal kicked off the 2021 cannabis merger-and-acquisition season, when Ireland-based Jazz Pharmaceuticals inked a $7.2-billion deal to acquire United Kingdom-based GW Pharmaceuticals, the manufacturer of the Food and Drug Administration-approved Epidiolex. It was the biggest handshake yet for the cannabis industry, and it could be just the beginning of what’s to come in a global market still in its infancy.

At Fox Rothschild, a Philadelphia-based law firm with a national cannabis practice group, Partner Melissa Sanders and Associate Jared Schwass told clients there is much more room for businesses to expand in an alert they released Feb. 1.

Sanders advises corporate clients on a wide range of business matters, with a particular focus on mergers and acquisitions, private placements of securities, financing transactions and ownership transition programs. Schwass is an attorney in the corporate department and a member of the firm’s Cannabis Law Practice Group. He advises businesses entering and operating in the legalized cannabis market on regulatory compliance, risk mitigation and business transactions.

“At the end of 2020, we saw an uptick in merger-and-acquisition activity as the industry shook off some pandemic-related instability, and we expect that trend to increase significantly in 2021,” they said in the alert.

“Despite abundant money available to the large multi-state operators (MSOs), most cannabis companies still have relatively limited avenues to raise capital due to the federal illegality of the industry,” they said. “However, that may change soon with the democrats now controlling both houses of Congress and the White House.”

When cannabis is descheduled, Sanders and Schwass said they anticipate an influx of cash into the sector, as previously reluctant investors and institutions enter the market without fear of federal repercussions.

Here, Sanders and Schwass share more about M&A activity trends, anticipations and indicators, and how MSOs and smaller businesses alike can position themselves for possible growth opportunities.                        

Tony Lange: What stood out most about how M&A activities shaped up in the 2020 cannabis industry?

Fox Rothschild | foxrothschild.com

Melissa Sanders, partner 

Melissa Sanders: I think we were seeing a lot of the distressed assets being snapped up. And even outside of the distressed assets, there were some good deals to be had. As we’re moving into 2021, that’s continuing. But I think that with the change in the Senate and legalization potentially on the forefront, additional capital is coming in and we’re going to see more M&A overall.

Jared Schwass: When COVID-19 first hit, there was kind of a lull in activity. Then, when medical necessities and distressed assets became available, that’s when the serial acquirers were buying up. And then we did see, towards the end, a couple of mergers that that were big news. I feel like more of that’s going to happen in 2021.

TL: How much would cannabis legislation at the federal level impact M&A activity?

MS: Federal legislation has some weight. I don’t want to overstate it, because we have to wait and see, but I do think it will bring in some potential money of folks who were still a little hesitant to maybe get into the business and essentially raise capital or put capital into other companies. The actual operators, they’ve already made the bet on cannabis. So, for them, a lot of it has been dependent on where the capital’s at.

JS: In addition to the increased capital that we can see, I believe with the descheduling on the Controlled Substances Act, that we’ll see major players outside of the cannabis industry start looking at trying to get into the industry.

TL: Regardless of the makeup of Congress, what are your anticipations for the rest of 2021?

MS: Regardless of what does happen at the federal level, I think M&A activity is going to be on the upswing. There are still a lot of good deals to be had out there. I also think people are anticipating and hopeful for an economic turnaround. So, deals are going to continue to happen and continue to grow.

I do think that we’re in a little bit of a different position than we were the last time there was this huge amount of M&A activity in the sense that companies are more mature. They’re seeing the things that maybe went wrong or weren’t ideal in former deals. So, although the increase is going to make for more competition for acquirers, I don’t think it’s going to be the same as it was in 2019, when people were really overlooking some real blemishes in companies just to keep growing and get in there. Now people really are looking at the fundamentals of the business and making sure they’ve got the corporate books and things like that.

-Melissa Sanders, Fox Rothschild partner 

JS: To add to that, regardless of what happens in Congress and the Senate, I think that M&A activity is going to still continue. We’re going to see a significant activity in that area, and there’s going to be a lot of consolidation in the coming years.

TL: Do you think small-scale cannabis businesses are a dying breed?

MS: I personally don’t think so, because there is a market for these independent companies and independent brands. That market is going to remain in cannabis and other industries. I do think that it’s going to be a lot harder for them to survive and compete, but I don’t think it’s a dying breed.

We’re still seeing a lot of small, one-off acquisitions. A lot of them are actually growing but not looking to necessarily become a huge MSO, although some of them are.

Fox Rothschild | foxrothschild.com

Jared Schwass, associate

JS: I don’t think it’s dying. I think it’s difficult, especially the small farmers up in Northern California are struggling. But I think through struggle comes perseverance. There is something to be said about these small farms and these small kind of craft brands that there still is a market for them, and there will continue to be a market for them.

TL: How can some of the small-scale cannabis businesses make themselves attractable for sale, if that’s the path they want to go?

MS: If they want to make themselves attractive, the biggest thing is getting everything in order, making sure they’ve got records or descriptions, depending on how old the company is; there was a time when companies weren’t keeping great records. If they don’t have them, they don’t have them, but getting whatever they do have in order, looking at where there are holes to the extent that they’re fixable, to work on those, and also just getting kind of all of their paperwork in order to make sure they’re tracking things will help. When an acquirer comes in, they’re going to want to do a lot of due diligence on the business and legal side. And, so, being able to present those materials quickly is important.

JS: I second that. Clean books are very important so there’s no questions on ownership or taxes or anything like that. And, generally speaking, good cashflow, not a lot of debt on the books, that type of stuff is important too.

TL: How can MSOs stay on top of the competitive M&A market so they can take advantage of opportunities as they arise?

MS: That’s a good question. A lot of it is just staying on top of who all of the operators are in the areas that make sense for you strategically. I think MSOs are going to acquire strategically this year, and making sure that they understand who the players are in each market, and whether those players might be open to sale, can help them approach the right people at the right time.

JS: Knowing who to acquire, what licenses, where, what states are opening up and doing your own market research is valuable in making sure that if you want to enter into a market in a different state, that that’s going to work for your business. Just doing your own due diligence and research in the market is essential to taking advantage of those opportunities.

TL: What sparks companies to decide whether a merger is right for them, or they’re better off pursing an acquisition?

MS: The same deal could really, in most cases, be structured as a merger or an acquisition just depending on certain legal points and tax points. I think we are seeing a lot of the larger deals as mergers, in large part because it’s going to be stock-for-stock and not a lot of cash. A lot of the stock deals are more merger-oriented and a lot of the cash deals may be structured as acquisitions, but that’s not 100% across the board. And definitely the smaller one-off deals, those are almost always structured as acquisitions and not mergers.

JS: Generally speaking, the bigger deals are to be more of a merger, when two bigger companies come together, whereas when you have a bigger company looking to just expand its market in a specific area, just buying a small business here and there, those are going to be obviously acquisitions.

TL: What states or regions do you forecast being hotbeds for M&A activity in the U.S.?

MS: I do think states that recently passed adult-use legalization, especially those that previously had medical programs, a lot of times there are going to be procedures for them to convert their companies, and those states will probably see M&A activity.

JS: California has a bunch of independent operators, and I believe the market is right for consolidation if companies can find synergies within themselves. Regardless of what happens in Congress, I think that we’re going to see continued M&A activity just because the market, the industry itself, is in its infancy and people are growing. But if the federal government decides to deschedule or legalize cannabis this year, I believe we will see a significant uptick in that activity.

Editor’s Note: This interview has been edited for style, length and clarity.

Filed Under: Cannabis News

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 57
  • Go to page 58
  • Go to page 59
  • Go to page 60
  • Go to page 61
  • Interim pages omitted …
  • Go to page 94
  • Go to Next Page »

Footer

  • Home
  • Privacy Policy
  • Terms of Service